Centinel Spine Commences US Evaluation of its New STALIF C(TM) Stand Alone Cervical IBF Device.

MINNEAPOLIS -- Centinel Spine, Inc. announced today that it has initiated US Alpha Site evaluation of the STALIF C[TM] NO PROFILE[TM] Stand Alone Cervical IBF Device for single level use in the treatment of cervical degenerative disc disease. The Company expects STALIF C[TM] to be available in early 2009, enabling spine surgeons to use the technology as an IBF device without supplementary fixation.

This evaluation is expected to take from one to two months and will determine when Centinel Spine will initiate the US sales launch of the STALIF C[TM] device in 2009. "The Alpha Site evaluation of the STALIF C[TM] is an important step of many steps needed for bringing this unique device to the US spine fusion market," said John J. Viscogliosi, Chairman & CEO of Centinel Spine, Inc. "We are pleased to reach a new milestone in the commercialization of STALIF C[TM], which we look forward to adding to our product portfolio."

About Centinel Spine, Inc.

Centinel Spine, Inc. is a leading global medical device company providing the PEEK-OPTIMA[R] STALIF TT[TM] and STALIF C[TM] technologies for Stand Alone Interbody Fusion (IBF) procedures. The STALIF TT[TM] and STALIF C[TM] technologies have been used in nearly 10,000 patients worldwide. The Company is dedicated to "Transforming Spine Surgeons' Ideas into Tomorrow's Technology." For more information, visit the Company website: www.centinelspine.com